Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3946 | Altiratinib | Balanced inhibitor for MET, TIE2 (TEK), and VEGFR2 (KDR) kinases | Inquire | |
| 1916 | AMG 208 | Inhibitor of c-MET receptor tyrosine kinase (RTK) | €95.00 | |
| 3945 | AMG-337 | Potent and exquisitely selective inhibitor of wild-type and some mutant forms of c-Met | Inquire | |
| 1838 | ARQ 197 | c-MET tyrosine kinase Inhibitor | €90.00 | |
| 4040 | BMS-777607 | potent, selective and orally bioavailable c-Met inhibitor | Inquire | |
| 3423 | Capmatinib | Highly potent, selective, ATP competitive and orally bioavailable c-MET inhibitor | €80.00 | |
| 1660 | Crizotinib | c-MET Inhibitor; NPM-ALK inhibitor | €70.00 | |
| 1582 | Foretinib | c-MET and VEGFR2 tyrosine kinase inhibitor | €90.00 | |
| 2553 | LY 2801653 | Orally bioavailable multi-kinase inhibitor with potent activity against c-MET | €120.00 | |
| 3975 | MGCD265 dihydrochloride | Orally active, potent MET/SMO dual inhibitor | €130.00 | |
| 1583 | PF 04217903 mesylate | c-MET tyrosine kinase Inhibitor | €80.00 | |
| 1914 | SGX 523 | ATP-competitive inhibitor of c-MET | €120.00 | |
| 1581 | SU 11274 | ATP-competitive inhibitor of c-MET | €90.00 | |
| 3864 | Volitinib dihydrochloride | ATP-competitive small molecule c-Met kinase inhibitor | Inquire | |